Phase 1 Clinical Trial Unit
Infectious disease therapeutics
In partnership with Quintiles, DynPort manages the NIAID Phase 1 Clinical Trial Unit to evaluate the safety of candidate therapeutic products.
Does your company have a biodefense or infectious disease therapeutic nearing Phase 1 clinical trials? Consider the National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 Clinical Trial Unit, managed by DynPort Vaccine Company and Quintiles.
About the Phase 1 unit
We evaluate the safety of candidate therapeutic products. Therapeutics may include those protecting against viral, bacterial, parasitic and fungal pathogens, and emerging infectious diseases.
- Project and clinical operations management
- Quality assurance
- Co-development of protocols
- Phase 1 clinical research and support for implementation
- Conduct approved Phase 1 clinical trial protocols
Principal Investigators, Division of Microbiology and Infectious Diseases (DMID) staff or outside collaborators may submit proposals for candidate therapeutics. You must submit your request directly to the NIAID Project Officer.
Have a candidate therapeutic?
- NIAID Phase 1 Clinical Trial Unit If you'd like to have your product considered, please contact the NIAID Project Officer directly.